| Literature DB >> 27983660 |
Jeon Woong Kang1, Surya P Singh2, Freddy T Nguyen3,4, Niyom Lue5, Yongjin Sung6, Peter T C So7,8,9, Ramachandra R Dasari10.
Abstract
Due to its label-free and non-destructive nature, applications of Raman spectroscopic imaging in monitoring therapeutic responses at the cellular level are growing. We have recently developed a high-speed confocal Raman microscopy system to image living biological specimens with high spatial resolution and sensitivity. In the present study, we have applied this system to monitor the effects of Bortezomib, a proteasome inhibitor drug, on multiple myeloma cells. Cluster imaging followed by spectral profiling suggest major differences in the nuclear and cytoplasmic contents of cells due to drug treatment that can be monitored with Raman spectroscopy. Spectra were also acquired from group of cells and feasibility of discrimination among treated and untreated cells using principal component analysis (PCA) was accessed. Findings support the feasibility of Raman technologies as an alternate, novel method for monitoring live cell dynamics with minimal external perturbation.Entities:
Keywords: Raman microscopy; Raman spectroscopy; cell imaging; therapeutic response monitoring
Year: 2016 PMID: 27983660 PMCID: PMC5191113 DOI: 10.3390/s16122133
Source DB: PubMed Journal: Sensors (Basel) ISSN: 1424-8220 Impact factor: 3.576
Figure 1(a) Schematic of high-speed confocal Raman microscopy system; and (b) axial resolution test by moving a 1-µm diameter polystyrene bead through the focal plane.
Figure 2Temporal monitoring of the same RPMI8226 cell after applying 50 nM Bortezomib at time zero (Scale bar: 5 µm): (A) bright field image; (B) confocal reflectance (binary mask is applied to target cell to eliminate the effect from outside of the cell); and (C) Four cluster Raman images. Different intracellular regions are marked.
Figure 3Mean baseline corrected spectra extracted from individual clusters annotated to an intracellular region in cluster Raman image: (a) Nucleus; (b) Perinuclear Region; and (c) Cytoplasm. Spectra are vertically offset for better visibility.
Figure 4Mean baseline corrected spectrum along with standard deviation (shaded region) acquired from group of cells: (A) Untreated; (B) Treated; (C) difference spectrum (Untreated − treated); and (D) PCA scatter plot.
Figure 5Loading plots of factors used for PCA.